These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18004247)

  • 1. Clinical impact of MDR1-expression in testicular germ cell cancer.
    Schrader AJ; Seger M; Konrad L; Olbert P; Hegele A; Hofmann R; Heidenreich A
    Exp Oncol; 2007 Sep; 29(3):212-6. PubMed ID: 18004247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Retroperitoneal lymph node dissection for patients with advanced testicular tumor].
    Takasaki N; Ueda H; Isurugi K
    Hinyokika Kiyo; 1994 Oct; 40(10):957-61. PubMed ID: 7992714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance of testis cancers: the study of clinical relevance of P-glycoprotein expression.
    Eid H; Bodrogi I; Csókay B; Oláh E; Bak M
    Anticancer Res; 1996; 16(6B):3447-52. PubMed ID: 9042205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urologic treatment of testicular germ cell cancer].
    Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
    Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
    Ulbright TM
    Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
    J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed orchiectomy at postchemotherapy retroperitoneal lymph node dissection due to laterality of retroperitoneal metastatic pattern consistent with testicular primary: assessment of pathologic findings.
    Brown JA; Bihrle R; Foster RS
    Urology; 2008 May; 71(5):911-4. PubMed ID: 18342916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
    Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
    Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
    Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
    J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.
    Steyerberg EW; Keizer HJ; Messemer JE; Toner GC; Schraffordt Koops H; Fosså SD; Gerl A; Sleijfer DT; Donohue JP; Habbema JD
    Cancer; 1997 Jan; 79(2):345-55. PubMed ID: 9010108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Retroperitoneal lymphadenectomy in disseminated non-seminoma germinogenic testicular tumors after chemotherapy in patients with elevated serum tumor markers].
    Matveev VB; Volkova MI; Cherniev VA; Figurin KM; Mitin AV
    Urologiia; 2010; (3):41-7. PubMed ID: 20734877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
    Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
    BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
    Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
    Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance and sensitivity of germ cell testicular tumors: evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins.
    Eid H; Géczi L; Mágori A; Bodrogi I; Institoris E; Bak M
    Anticancer Res; 1998; 18(4C):3059-64. PubMed ID: 9713510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
    Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein.
    Peterson M; Beck S; Bihrle R; Einhorn L; Foster R
    BJU Int; 2009 Jul; 104(2):176-8. PubMed ID: 19493258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.